Drug Discovery & DDS– category –
-
Closing the Innovation Gap: Early CMC Risk Management and Robust Conjugation Strategies for ADCs and AOCs
Industry Publication Unknown Overview As Antibody-Drug Conjugates (ADCs) and Oligonucleotide-Drug Conjugates (AOCs) rapidly expand beyond oncology, early identification of Chemistry, Manufacturing, and Controls (CMC) risks and establishi... -
Hongene Biotech Leverages Chemoenzymatic Ligation to Scale CRISPR sgRNA Manufacturing
Industry Publication / Hongene Biotech Unknown Overview Hongene Biotech is pioneering a chemoenzymatic ligation technology to address the critical scalability challenges in producing single-guide RNA (sgRNA) for CRISPR gene editing. This... -
ChemCopilot’s Generative AI Translates Natural Language to SMILES, Automating Molecular Design
ChemCopilot Unknown Overview ChemCopilot has launched a groundbreaking generative AI model for molecular design, capable of translating natural language prompts into stable SMILES strings. This innovative system automates the entire work... -
Oral GLP-1 Agonist Elecoglipron Achieves Landmark 11.8% Weight Loss and Superior Glycemic Control in Phase 2 Trial
News-Medical.Net 他 USA Overview The oral GLP-1 receptor agonist elecoglipron delivered compelling results in its Phase 2b SOLSTICE clinical trial, achieving up to 11.8% dose-dependent body weight reduction and significantly improving gl... -
Efficient Prime Editing In Vivo and In Vitro Demonstrated with Lipid Nanoparticles: High Efficacy, Low Off-Target Effects
PubMed International Overview Recent research reports the development of an optimized platform for prime editing using lipid nanoparticles (PE-LNP), demonstrating high gene editing efficiency in vivo. This LNP-based system offers a compe... -
Bispecific Antibody Ivonescimab Plus Chemotherapy Significantly Improves Overall Survival in EGFR-Mutant NSCLC: HARMONi-A Phase 3 Results Published in JAMA
PubMed (JAMA) International Overview Final results from the Phase 3 HARMONi-A clinical trial, published in JAMA, demonstrate a breakthrough in EGFR-mutant non-small cell lung cancer (NSCLC) treatment. Combination therapy with the bispeci... -
Mabwell’s World-First LILRB4/CD3 Bispecific Antibody 6MW5311 Receives FDA Clinical Trial Clearance for Hematologic Malignancies
Mabwell (press release) China Overview Mabwell has secured FDA Clinical Trial Application (CTA) clearance for 6MW5311, a LILRB4/CD3-targeting T-cell engager (TCE) bispecific antibody, for hematologic malignancies including AML, CMML, and... -
Arvinas Accelerates Clinical Development of ARV-027 for Kennedy’s Disease, Targeting Mutant Androgen Receptor Degradation with PROTAC
Kennedy's Disease Association USA Overview Arvinas is steadily advancing the clinical development of ARV-027, an investigational PROTAC degrader for Kennedy's Disease (Spinal and Bulbar Muscular Atrophy, SBMA). ARV-027 is designed to sel... -
University of Houston Discovers ‘Salt-Loaded LNPs’ to Overcome Major Gene Therapy Obstacle by Enhancing Endosomal Escape
University of Houston USA Overview Researchers at the University of Houston have made a groundbreaking discovery to improve intracellular delivery of genetic material, a major hurdle in gene therapy. They developed 'salt-loaded lipid nan... -
Boltz Forms AI Drug Discovery Partnership with Takeda to Boost Molecular Design with Novel Biomolecular Foundation Models
FirstWord HEALTHTECH Japan Overview Boltz has announced a strategic AI drug discovery partnership with Takeda Pharmaceutical Company. This collaboration will integrate Boltz's new biomolecular foundation models, BoltzMol-1 for small mole...
